Working with experts in glycosylation chemistry, Acretia has helped to launch Biousian Biosystems Inc (BBI). BBI uses its synthetic glycosylation chemistry platform (CarboSyn) to develop GPCR targeted products. Providing seed capital and Rx development support, Acretia hopes to see BBI’s lead programs targeting several pain indications move toward clinical trials.
Home
Acretia is an drug development company that bridges the gap between
leading medical research centers and biopharmaceutical industry. We are dedicated to
help bring revolutionary products to the market and to patients in need.
Partnering
In-Licensing
Acretia is dedicated to building a dynamic and effective partnership with technology transfer professionals, academic and clinical experts at the leading academic medical research centers. Learn more
R&D
Acretia is an emerging drug development organization focused on translational medicine and believes that scale-by-alliance is critical to success in the next era of the biopharmaceutical industry. Learn more
Co-development and Marketing
Acretia identifies, acquires and clinically validates proprietary pharmaceutical products and then seeks to bring them through FDA registration and marketing via alliances with pharmaceutical partners. Acretia offers to its alliance partners preclinial and clinically validated compounds with fully integrated drug development programs with all associated "pharma-ready" data and relationships. Learn more
News
"Sweetening” Pharmacology of Peptides